(Q38091664)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23516024%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

title

Multifocal motor neuropathy: current therapies and novel strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23516024%20AND%20SRC:MED&resulttype=core&format=json

Multifocal motor neuropathy

26 February 2020

main subject

1 reference

inferred from title

author

Eduardo Nobile-Orazio

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23516024%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Francesca Gallia

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23516024%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

publication date

1 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23516024%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23516024%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23516024%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23516024%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

397-406

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23516024%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40265-013-0029-z

26 February 2020

exact match

0 references

cites work

Multifocal motor neuropathy: current concepts and controversies.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

The sensitivity and specificity of anti-GM1 antibody testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Transcutaneous cervical root stimulation in the diagnosis of multifocal motor neuropathy with conduction block

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Activity-dependent conduction block in multifocal motor neuropathy: magnetic fatigue test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Acute conduction block in vitro following exposure to antiganglioside sera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Multifocal motor neuropathy human sera block distal motor nerve conduction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Multifocal motor neuropathy: response to human immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

How long is IVIg effective in multifocal motor neuropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Axon loss is an important determinant of weakness in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Subcutaneous immunoglobulin therapy for multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Pe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

A syndrome of asymmetric limb weakness with motor conduction block

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Multifocal motor neuropathy with conduction block: a study of 24 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Mycophenolate mofetil in dysimmune neuropathies: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Invited article: inhibition of B cell functions: implications for neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Treatment of IgM antibody associated polyneuropathies using rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Beneficial effect of rituximab monotherapy in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

An open-label trial of rituximab (Rituxan®) in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

An open label clinical trial of complement inhibition in multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Recent developments in low molecular weight complement inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Motor Neuropathy with Proximal Multifocal Persistent Conduction Block, Fasciculations and Myokymia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0029-Z

Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients

21 January 2018

1 reference

12 December 2020

Deterioration of multifocal motor neuropathy after plasma exchange

1 reference

12 December 2020

The clinical value of therapeutic plasma exchange in multifocal motor neuropathy

1 reference

12 December 2020

No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy

1 reference

12 December 2020

[Improvement of severe and intravenous immunoglobulin-dependent multifocal motor neuropathy with conduction block after long-term rituximab]

1 reference

12 December 2020

Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome

1 reference

12 December 2020

Intravenous immunoglobulin treatment in multifocal motor neuropathy

1 reference

12 December 2020

A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside

1 reference

12 December 2020

Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study

1 reference

12 December 2020

Multifocal motor neuropathy presenting as ophthalmoplegia

1 reference

12 December 2020

Experimental conduction block induced by serum from a patient with anti-GM1 antibodies

1 reference

12 December 2020

Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies

1 reference

12 December 2020

Efficacy of cyclosporine treatment in multifocal motor neuropathy

1 reference

12 December 2020

Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis

1 reference

12 December 2020

Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy

1 reference

12 December 2020

Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy

1 reference

12 December 2020

Triple-stimulation technique in multifocal neuropathy with conduction block

1 reference

12 December 2020

Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment

1 reference

12 December 2020

Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab

1 reference

12 December 2020

Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg

1 reference

12 December 2020

Association of IgM type anti-GM1 antibodies and muscle strength in chronic acquired demyelinating polyneuropathy

1 reference

12 December 2020

Consensus criteria for the diagnosis of multifocal motor neuropathy

1 reference

12 December 2020

Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial

1 reference

12 December 2020

Chronic acquired demyelinating motor neuropathy

1 reference

12 December 2020

Are anti-ganglioside antibodies of clinical value in multifocal motor neuropathy?

1 reference

12 December 2020

Oral methotrexate as adjunctive therapy in patients with multifocal motor neuropathy on chronic IVIg therapy

1 reference

12 December 2020

Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy

1 reference

12 December 2020

Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy

1 reference

12 December 2020

Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy

1 reference

12 December 2020

Intravenous immunoglobulin for multifocal motor neuropathy

1 reference

12 December 2020

Motor nerve conduction study in cauda equina with high-voltage electrical stimulation in multifocal motor neuropathy and amyotrophic lateral sclerosis

1 reference

12 December 2020

Treatment of multifocal motor neuropathy with interferon-beta1A

1 reference

12 December 2020

Intravenous immunoglobulin for multifocal motor neuropathy

1 reference

12 December 2020

Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg

1 reference

12 December 2020

Interferon beta-1a as adjunctive treatment for multifocal motor neuropathy: an open label trial

1 reference

12 December 2020

Immunosuppressive treatment in multifocal motor neuropathy

1 reference

12 December 2020

IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN

1 reference

12 December 2020

European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first

1 reference

12 December 2020